DDInter1562 DDInter1951
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. However, it has a negligible effect on altering the development and progression of breast cancer itself.[label] The most common causes of osteoporosis
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Raloxifene {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Warfarin
Raloxifene {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Warfarin
Raloxifene {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Warfarin
Raloxifene {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Raloxifene {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Benzyl Benzoate
Benzyl Benzoate {u} (Compound) resembles {v} (Compound) Warfarin
Raloxifene {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Raloxifene {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Raloxifene {u} (Compound) downregulates {v} (Gene) NUP85
NUP85 {u} (Gene) is downregulated by {v} (Compound) Pheniramine
Pheniramine {u} (Compound) resembles {v} (Compound) Warfarin
Raloxifene {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Raloxifene {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Erlotinib
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Raloxifene (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Warfarin (Compound)
Raloxifene (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Warfarin (Compound)
Raloxifene (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Warfarin (Compound)
Raloxifene (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin
Raloxifene (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Benzyl Benzoate (Compound) and Benzyl Benzoate (Compound) resembles Warfarin (Compound)
Raloxifene (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Raloxifene (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Fluvastatin (Compound) and Fluvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin
Raloxifene (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Pheniramine (Compound) and Pheniramine (Compound) resembles Warfarin (Compound)
Raloxifene (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin
Raloxifene (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Erlotinib (Compound) and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin